It was the question considered by an Australian federal court judge who on Friday ruled that a U.S. biotech company was within its rights to hold Australian patent 686004.
The lawsuit, the first of its kind in Australia, was filed against two biotech companies, U.S.-based Myriad Genetics, which owns the patent, and Genetic Technologies in Melbourne, which has exclusive rights to the testing in Australia and New Zealand.
Supreme court to hear case in U.S.
She said Cancer Voices Australia would be pushing for an amendment to Australian law to cover human genes.
That's what we will be advocating for and supporting," she said.